Search research articles
Contact Us
Filters
Showing results (21-30 of 239) with videos related to
Page
of 24
Sort By:
Pharmacotherapy
|
November 28, 2006
Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder
Yu Ko, Daniel C Malone, Edward P Armstrong
International Journal of Hematology
|
September 24, 2013
Evaluating the efficacy and safety of apixaban, a new oral anticoagulant, using Bayesian meta-analysis
Lorenzo A Villa, Daniel C Malone, Daniel Ross
Journal of Medical Economics
|
April 20, 2026
Cost-effectiveness analysis of capivasertib plus fulvestrant in the <i>PIK3CA/AKT1/PTEN</i>-altered subgroup with HR+/HER2- advanced breast cancer: a United States payer perspective
Xi Liang, Daniel C Malone, Chia Jie Tan
Journal of Managed Care Pharmacy : JMCP
|
August 23, 2013
Effect of an educational outreach program on prescribing potential drug-drug interactions
Daniel C Malone, Joshua N Liberman, Diana Sun
Journal of Managed Care Pharmacy : JMCP
|
July 2, 2004
Cost-effectiveness analysis of simvastatin and lovastatin/extended- release niacin to achieve LDL and HDL goal using NHANES data
Edward P Armstrong, Woodie M Zachry, Daniel C Malone
Pharmacotherapy
|
March 31, 2012
Recommendations for generating, evaluating, and implementing drug-drug interaction evidence
Lisa E Hines, Daniel C Malone, John E Murphy
The American Journal of Emergency Medicine
|
March 24, 2022
Risk of tizanidine-induced adverse events after concomitant exposure to ciprofloxacin: A cohort study in the U.S
Theodoros V Giannouchos, Ainhoa Gómez-Lumbreras, Daniel C Malone
Journal of Medical Economics
|
September 25, 2012
Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder
Edward P Armstrong, Daniel C Malone, Cat N Bui
Journal of Managed Care Pharmacy : JMCP
|
October 1, 2005
Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C
Daniel C Malone, Tram T Tran, F Fred Poordad
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 21, 2019
Per-Prescription Drug Expenditure by Source of Payment and Income Level in the United States, 1997 to 2015
Wenxi Tang, Jing Xie, Fanxin Kong, et al.
Page
of 24
Search research articles
Search
Showing results (21-30 of 239) with videos related to
Sort By:
Page
of 24
Pharmacotherapy
|
November 28, 2006
Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder
Yu Ko, Daniel C Malone, Edward P Armstrong
International Journal of Hematology
|
September 24, 2013
Evaluating the efficacy and safety of apixaban, a new oral anticoagulant, using Bayesian meta-analysis
Lorenzo A Villa, Daniel C Malone, Daniel Ross
Journal of Medical Economics
|
April 20, 2026
Cost-effectiveness analysis of capivasertib plus fulvestrant in the <i>PIK3CA/AKT1/PTEN</i>-altered subgroup with HR+/HER2- advanced breast cancer: a United States payer perspective
Xi Liang, Daniel C Malone, Chia Jie Tan
Journal of Managed Care Pharmacy : JMCP
|
August 23, 2013
Effect of an educational outreach program on prescribing potential drug-drug interactions
Daniel C Malone, Joshua N Liberman, Diana Sun
Journal of Managed Care Pharmacy : JMCP
|
July 2, 2004
Cost-effectiveness analysis of simvastatin and lovastatin/extended- release niacin to achieve LDL and HDL goal using NHANES data
Edward P Armstrong, Woodie M Zachry, Daniel C Malone
Pharmacotherapy
|
March 31, 2012
Recommendations for generating, evaluating, and implementing drug-drug interaction evidence
Lisa E Hines, Daniel C Malone, John E Murphy
The American Journal of Emergency Medicine
|
March 24, 2022
Risk of tizanidine-induced adverse events after concomitant exposure to ciprofloxacin: A cohort study in the U.S
Theodoros V Giannouchos, Ainhoa Gómez-Lumbreras, Daniel C Malone
Journal of Medical Economics
|
September 25, 2012
Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder
Edward P Armstrong, Daniel C Malone, Cat N Bui
Journal of Managed Care Pharmacy : JMCP
|
October 1, 2005
Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C
Daniel C Malone, Tram T Tran, F Fred Poordad
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 21, 2019
Per-Prescription Drug Expenditure by Source of Payment and Income Level in the United States, 1997 to 2015
Wenxi Tang, Jing Xie, Fanxin Kong, et al.
Page
of 24